Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500.
MR angiograms (top row) of the right coronary arteries in two persons living with HIV (PLWH) show location of cross-section (dotted lines) of coronary vessel wall image (bottom row) and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback